Experimental treatment modalities for liver failure
Sosef, M.N.

Citation for published version (APA):
Sosef, M. N. (2003). Experimental treatment modalities for liver failure
Chapter 2

Total hepatectomy model in pigs:
Revised method for vascular reconstruction
using a rigid vascular prosthesis

Sosef MN and van Gulik TM
Department of Surgery (Surgical laboratory)
Academic Medical Center, Amsterdam
In press, European Surgical Research
ABSTRACT

Total hepatectomy in animals provides an irreversible model of acute liver failure. Vascular reconstruction in this model of acute liver failure was modified and characterized for the use of assessment of liver support systems.

Pigs underwent total hepatectomy and a rigid 3-way transparent polyethylene vascular conduit was used to replace the retrohepatic caval vein and to shunt the portal venous blood to the caval vein. Placement of the vascular conduit in conjunction with excision of the liver was completed in 10-22 minutes without the need of a temporary veno-venous bypass. A survival study conducted in five animals showed a mean survival time of 46 ± 6 hours. Baseline and 4 hours postoperative hemoglobin levels were not different, and plasma ammonia levels rose to more than 30-fold of baseline values. All animals died of cardiac arrhythmias and irreversible shock.

Total hepatectomy in the pig using a 3-way, portal-venous conduit is a reliable and well-reproducible animal model of acute liver failure for evaluation of liver assist devices.

INTRODUCTION

In the development of a bioartificial liver (BAL), one of the essential steps to be taken before clinical application is assessment of its efficacy and safety in a large animal model of fulminant hepatic failure. A variety of animal models of hepatic failure have been elaborated in the past, based on liver devascularization, total hepatectomy, the administration of hepatotoxic drugs or a combination of surgical and intoxication models. However, none of these models is able to entirely mimic the pathophysiology of fulminant hepatic failure in humans and is sufficiently reproducible as well.

The total hepatectomy model renders an anhepatic animal. Advantages of the anhepatic model are its clarity, reproducibility and its potential to assess the biochemical capacity of a bioartificial liver device in vivo in the absence of toxic products leaking out of, or produced by the native liver. Obviously, the release of products of necrosis and signal transmitters, seen as an important factor in the pathophysiology of fulminant liver failure, is absent in the anhepatic model.

Application of the anhepatic model in pigs requires reconstruction of the caval vein in combination with drainage of the portal venous system to prevent splanchnic congestion. The intrahepatic part of the caval vein is either dissected off the liver in combination with a portocaval shunt, or is excised in conjunction with the whole liver, followed by reconstruction of vascular portal-caval and caval-caval continuity. Usually, a Dacron prosthesis has been used as a vascular conduit[1,2].

In an initial study, the anhepatic pig model as described by Mazziotti was used in our institution to evaluate a newly devised, bioartificial liver (AMC-BAL)[1]. A total hepatectomy was performed after construction of a portocaval shunt. Caval continuity was restored with use of a Dacron prosthesis. In order to assess at least 24 hours of treatment with the AMC-BAL, the animals remained anaesthetized and mechanically ventilated until death. All four animals of this series showed severe coagulation disorders after 24-30 hours, with continuous and diffuse bleeding through the vascular anastomoses and
through the mesh of the dacron prosthesis. This limitation of the animal model prompted us to develop a technique of vascular reconstruction using a rigid polyethylene three-way prosthesis. The concept is based on the Y-shaped Pyrex-glass cannula as used by Firor and Stinson in 1929 with total hepatectomy in dogs[3].

The aim of this study was to assess the efficacy of a self-made, three-way prosthesis after total hepatectomy in pigs and at the same time, characterize this anhepatic model for prolonged assessment of liver assist devices.

METHODS

Adult white female pigs were used, weighing between 37 and 71 kg (mean 51 ± 9 kg). All procedures were approved by the institutional guidelines of the Animal Ethical Committee of the University of Amsterdam.

Anesthesia

After fasting overnight, induction of anesthesia was achieved with intramuscular administration of ketamine (10mg/kg; Nimatec®, Eurovet, Bladel, the Netherlands), azaperon (2 mg/kg; Stresnil®, Janssen Pharmaceutica, Tilburg, The Netherlands) and atropine (0.02 mg/kg). After inhalation of a mixture of O₂:NO₂ (2:3) and isoflurane (0.4-1%, Abbott Laboratories Ltd., Queensborough, UK), pigs were intubated with a cuffed endotracheal tube and ventilated on a mixture of O₂ and air. Anesthesia was maintained by intravenous administration (0.5 ml/kg/hour, after total hepatectomy 0.2 ml/kg/hour) of a mixture of sufentanilcitrate (20mg/l, Janssen-Cilag, Tilburg, the Netherlands) and ketamine (20g/l). Muscle relaxation was obtained by intravenous administration (2ml/h) of pancuronium bromide (2 mg/ml, Organon Teknika B.V., Boxtel, The Netherlands). Arterial and venous lines were inserted in the right axillary artery and internal jugular vein for blood sampling and for continuous monitoring of arterial pressure and central venous pressure, respectively.

Surgical procedure

A laparotomy was performed using an abdominal midline incision. A urine catheter was sutured in the bladder in order to monitor urine production. The liver was freed of all peritoneal attachments. The common bile duct and hepatic arteries were ligated and transected. The suprahepatic cava, suprarenal cava and portal vein were dissected free, with careful ligation of the remaining lymphatic tissue in the hepatoduodenal ligament. The vascular prosthesis used was 15 cm long, made of transparent polyethylene with an inner diameter of 12 mm (caval vein junction sites) and 10 mm (portal site). Parts were glued together, and a Luer Lock connection point in the portal part allowed temporary insertion of a Ch 6 occlusion balloon in the caval part. The prosthesis was sterilized in glutaraldehyde solution, washed thoroughly and flushed with a heparin solution (10 U/ml, Leo BV, Weesp, The Netherlands) before use.

The portal vein was cross-clamped and cannulated (marking the start of the anhepatic state) after which the liver was flushed with 1000 ml of cold (4°C) Ringers glucose solution (NPBI, Emmer Compascuum, the Netherlands). After subsequent temporary clamping of the suprhepatic and infrahepatic caval vein, the rigid three-way prosthesis was inserted upwards through a caval venotomy, passing the entry sites of the
hepatic veins and fixed cranially and caudally of the liver with tourniquets around the caval vein. Caval blood flow was restored after desufflation, unclamping and retraction of the occlusion balloon in the portal part of the prosthesis. Portal blood flow was subsequently shunted to the systemic circulation by connecting the portal vein to the side-port of the prosthesis, after which the balloon could be removed (figure 1). The liver was removed in toto after incising the circumferences of suprahepatic and infrahepatic caval vein and in between these margins, the posterior wall of the caval vein. The transparency of the prosthesis allowed visual assessment of portocaval blood flow. No decompressive venous bypass was required. No blood transfusions were given during the procedure.

Figure 1.

Schematic drawing of the rigid prosthesis, serving as a vascular conduit between portal and caval veins after total hepatectomy.
Postoperative care
Postoperatively, all animals were kept under full anesthesia until death. Fluids were administered intravenously as clinically indicated (electrolyte solutions and Ringers lactate, NPBI, Emmer Compascuum, The Netherlands; eloHaes, Fresenius BV, 's-Hertogenbosch, The Netherlands). Phenylephrine (10 mg/ml; 2-25 ml/h) was administered intravenously when necessary to maintain mean arterial blood pressure above 55 mmHg. Animals were kept on volume controlled, positive pressure ventilation during the experiment. Inspiratory peak pressure, capnography, direct arterial blood pressure, and central venous blood pressure were monitored continuously and corrected to physiological values. Body temperature was maintained at 38°C using a heated mattress. A 20% glucose solution was infused when plasma glucose levels fell below 8 mmol/l. Every 12 hours, the animals received 1 gram of ceftriaxon iv (Roche, Basel, Switzerland). Autopsy was ultimately performed in all animals.

Laboratory assessments
Arterial blood samples were obtained preoperatively, at the moment of total hepatectomy (defined as t=0 h) and at 4 hourly intervals post-hepatectomy until death, for determination of hemoglobin, leukocyte and thrombocyte count, albumin, lactate, kreatinin, BUN, AST, ALT, ammonia and prothrombin time by standard laboratory techniques. Ammonia was measured by means of a spectrophotometric method (ACA SX, Dupont).

RESULTS
A total hepatectomy with use of the rigid prosthesis was performed in 20 animals. The surgical procedure proved to be relatively easy and straightforward, with a short learning curve of 2 to 3 animals. Time between clamping of the portal vein and complete restoration of portocaval blood flow was 16 ± 4 minutes (mean ± SD; range 10-22 minutes). Intraoperative blood loss was 270 ± 225 ml, including electrolyte solution leaking out of the cava during excision of the liver. During clamping of the caval and portal veins progressive hypotension and tachycardia was observed, with mean arterial pressures of approximately 40 mmHg after 8-10 minutes. After restoration of flow, a good hemodynamical recovery was seen in all animals. Bowels regained their normal color within 2 minutes after unclamping the portal vein.

Technical problems let to the termination of the experiments in three animals: one caval lesion during dissection prior to placement of the prosthesis, one portal vein laceration and one gastric congestion and bleeding after tying the splenic vein (learning curve). Two experiments were terminated because of infectious complications: one pneumonia, and one Pseudomonas spp. septicemia. Five anhepatic animals received postoperative supportive treatment until death including positive pressure ventilation, and showed a mean survival time of 46 ± 6 hours (37, 41, 50, 50 and 51 hr). In order to control hypotension, phenylephrine was administered starting 20-24 hours after hepatectomy, resulting in a progressive tachycardia (figure 2). Eventually, all animals died due to irreversible shock or cardiac arrhythmias.

Hemoglobin levels 4 hours post-hepatectomy did not significantly differ from baseline values (5.0 vs 5.1 mmol/l resp.). Baseline and postoperative laboratory values are
reported in table 1. Hemoglobin, thrombocyte count and albumin show a gradual decrease to 35-45% of baseline values just before death. Blood ammonia levels gradually rose more than 30-fold, while lactate levels only increased a few hours before death when the animals became hemodynamical unstable and required high dose of inotropics vasopressor agents.

At autopsy, no signs of portal congestion were noticed. 100-350 ml of serosanguinolent fluid was found in the abdominal cavity of all animals. All grafts were patent without signs of thrombosis and there were no signs of bleeding from the connection sites between prosthesis and veins. Brain autopsy was not performed.

The remaining 10 animals were connected to the AMC-bioartificial liver for evaluation of its efficacy in the anhepatic pig as has been reported elsewhere[4].

Figure 2.
Mean (± SD) arterial pressure (mmHg, lower line) and heart-rate (bpm, upper line) after total hepatectomy (at T = 0 h). Phenylephrine was used when clinically indicated.
<table>
<thead>
<tr>
<th></th>
<th>Baseline (mmol/l)</th>
<th>Td -36</th>
<th>Td -24</th>
<th>Td -12</th>
<th>Td -4</th>
<th>Td</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>5.14 ± 0.51</td>
<td>4.76 ± 1.23</td>
<td>4.46 ± 0.96</td>
<td>3.93 ± 1.23</td>
<td>2.78 ± 1.15</td>
<td>2.33 ± 0.87</td>
</tr>
<tr>
<td>Leucocytes (10E9/l)</td>
<td>12 ± 2.4</td>
<td>28 ± 4.1</td>
<td>33 ± 11.6</td>
<td>28 ± 12.7</td>
<td>27 ± 9.7</td>
<td>23 ± 10.8</td>
</tr>
<tr>
<td>Thrombocytes (10E12/l)</td>
<td>267 ± 68</td>
<td>216 ± 64</td>
<td>161 ± 54</td>
<td>131 ± 58</td>
<td>106 ± 19</td>
<td>95 ± 13</td>
</tr>
<tr>
<td>Albumin (g/l)</td>
<td>28 ± 2.9</td>
<td>17 ± 2.9</td>
<td>15 ± 4.0</td>
<td>15 ± 3.8</td>
<td>12 ± 4.2</td>
<td>10 ± 3.3</td>
</tr>
<tr>
<td>Lactate (mmol/l)</td>
<td>1.10 ± 0.47</td>
<td>1.54 ± 0.58</td>
<td>1.75 ± 0.47</td>
<td>1.95 ± 0.66</td>
<td>2.55 ± 0.72</td>
<td>5.63 ± 3.71</td>
</tr>
<tr>
<td>Kreatinin (g/l)</td>
<td>82 ± 17</td>
<td>95 ± 17</td>
<td>80 ± 15</td>
<td>121 ± 38</td>
<td>153 ± 58</td>
<td>186 ± 67</td>
</tr>
<tr>
<td>BUN</td>
<td>2.84 ± 1.30</td>
<td>1.22 ± 0.82</td>
<td>1.08 ± 0.55</td>
<td>1.25 ± 0.53</td>
<td>1.50 ± 0.75</td>
<td>1.70 ± 0.59</td>
</tr>
<tr>
<td>AST (U/l)</td>
<td>25 ± 12</td>
<td>198 ± 74</td>
<td>220 ± 5</td>
<td>280 ± 109</td>
<td>253 ± 86</td>
<td>258 ± 81</td>
</tr>
<tr>
<td>ALT (U/l)</td>
<td>38 ± 12</td>
<td>36 ± 12</td>
<td>35 ± 14</td>
<td>34 ± 12</td>
<td>27 ± 10</td>
<td>26 ± 9</td>
</tr>
<tr>
<td>Ammonia (mol/l)</td>
<td>57 ± 32</td>
<td>372 ± 94</td>
<td>322 ± 96</td>
<td>636 ± 429</td>
<td>1347 ± 888</td>
<td>1843 ± 1215</td>
</tr>
<tr>
<td>PT (sec)</td>
<td>11 ± 0.4</td>
<td>19 ± 4.4</td>
<td>&gt; 40</td>
<td>&gt; 40</td>
<td>&gt; 40</td>
<td>&gt; 40</td>
</tr>
</tbody>
</table>

Table 1.
Baseline laboratory blood values compared with values at different time points (hours) before death (Td). No blood transfusions or albumin suppletion were given.

DISCUSSION

This study describes a modified surgical technique of performing a total hepatectomy in pigs, to serve as an animal model of acute liver failure that is suitable for testing of temporary liver support treatments. For a limited number of animals, the postoperative course until death is reported in detail.

Unfortunately, there is no animal model of acute liver failure that is pathophysiologically and metabolically identical to fulminant hepatic failure in humans, and is at the same time well reproducible and potentially reversible. Specific study objectives and questions will ultimately lead to the choice of a suitable animal model. The most frequently employed models use high doses of hepatotoxins such as galactosamine and acetaminophen, or are based on surgical anhepatic or devascularization procedures.

Drug-toxicity models probably provide the most clinically relevant models for studies on the disease itself. An important disadvantage which is especially relevant in controlled treatment studies, is the difficulty of reproducibility and extrahepatic hepatotoxicity[5]. Surgical models have less pathophysiologic similarities with fulminant hepatic failure than toxic models, but are easier to reproduce and, in case of total hepatectomy, offer a way to measure absolute function of a bioartificial liver device in vivo. They can be separated into those that provide functional hepatectomy, leaving ischemic liver in situ deprived of its afferent blood supply, or techniques that involve anatomic excision of the liver. Functional hepatectomy involves creating a terminal portal-caval shunt and (in a one-stage procedure or in separate steps) skeletonizing the whole liver with ligation of the hepatic artery and all other, collateral arterial branches. This complete liver ischemia model resembles clinical fulminant failure to the extent that
the failing liver remains in situ and is allowed to release products of necrosis in the systemic circulation, which allegedly are responsible for the toxic syndrome of acute liver failure. Survival times of up to $33.1 \pm 3$ h hours (mean $\pm$ SEM) have been shown in pigs with complete liver ischemia[6], as compared to survival times of up to 27 hours in pigs rendered anhepatic[2].

Mann and Magath, in 1921, were the first to perform a total hepatectomy in dogs[7], and were followed by other groups reporting on total hepatectomies in rats[8,9] and pigs[2,10,11]. The main objectives of the earlier studies were to study metabolism of the liver and the pathophysiology of the anhepatic state. Development and refinement of treatment regimes of hepatic failure were a second objective, now experiencing renewed interest with the recent development of bioartificial livers. The pig is the most suitable, large animal to evaluate liver support systems because of, among other reasons, its close anatomical, physical and biochemical resemblance to humans. The use of a knitted, Dacron prosthesis for vascular reconstruction after total hepatectomy in pigs, led to severe bleeding complications after 24-30 hours of anhepatic state, imposing significant limitations to the model and therefore, was abandoned in this study.

The procedure described in this study proves to be straightforward and safe. The limited variation in survival times and the continued, postoperative supportive care offer a therapeutic window suitable for assessment of treatment with a bioartificial liver. The hepatectomy involved a relatively minor surgical trauma as demonstrated by the rapid stabilization of the animal after surgery. Blood transfusions were not necessary owing to minimal intraoperative blood loss and flushing of the liver prior to clamping of the caval veins. The significant decrease in albumin levels can be attributed to lacking production of albumin as well as intra-abdominal leakage of lymphatic fluid, despite accurate ligation of the lymphatic vessels in the hepatoduodenal ligament and the peritoneal adhesions. Assessment of ICP was attempted in the initial series but was relinquished because of severe bleeding problems at the craniotomy site with prolonged duration of the anhepatic state.

Terblanche and coworkers stated six criteria for a satisfactory animal model of fulminant hepatic failure: 1. Reversibility (animals should be able to survive if a suitable treatment were to be utilized), 2. Reproducibility, 3. Death from liver failure, 4. Adequate therapeutic window (large enough to assess effects of treatment), 5. Large animal type of model and 6. Minimal hazard to personnel[12]. Clearly, the first criterion cannot be matched in the anhepatic model. Our data show that the employed technique of total hepatectomy in pigs meets the other five criteria. Advantages of our prosthesis are the simple procedure for insertion combined with minimal blood loss, and its transparency in order that blood flow can be checked after placement. Furthermore, there is no need for temporary venous decompression owing to short clamping times. The tight tourniquets that fix the prosthesis to the veins abolish bleeding complications even in situations after prolonged anhepatic state when blood coagulation is close to absent.

In conclusion, application of a 3-way, polyethylene vascular prosthesis in conjunction with total hepatectomy provides a reliable, safe and effective animal model of acute liver failure allowing the evaluation of liver assist devices for an extended period of time. Longer survival times have been achieved with this prosthesis, when compared with the knitted, Dacron prosthesis.
References


